(Q35058697)

6 August 2017

1 reference

title

Imatinib alone and in combination for chronic myeloid leukemia (English)

1 reference

6 August 2017

chronic myeloid leukemia

0 references

1 reference

1 reference

Brian J Druker

1

0 references

publication date

1 January 2003

1 reference

6 August 2017

Seminars in Hematology

1 reference

6 August 2017

40

1 reference

6 August 2017

50-58

1 reference

6 August 2017

1

1 reference

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970042-0

7 January 2021

10.1016/S0037-1963(03)70042-0

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12563611